Larimar Therapeutics to host investor event on June 29

Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced it will host an investor webcast on June 29, 2026, at 7:45 a.m. ET to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia.

The event is expected to include a regulatory update and data from the company's ongoing long-term open-label study of nomlabofusp, which is being developed as a potential treatment for adults and children with Friedreich's ataxia.

An archived recording of the webcast will be made available on the company's website following the live event.

You May Also Be Interested In

• ECB Officials Are Ready To Raise Interest Rates In September - Bloomberg
• Iran flew IRGC commanders, missile gear to Yemen's Houthis - Reuters
• Benchmark on Knight Transportation (KNX) Stock: Any Pullback a Buying Opportunity